Fall has arrived and during September the pace of business changes. Summer is over, the team is back out in the field, and the questions a leader brings to the first business review of the month are sharper what was asked in July and August. Where are we ahead? Where are we behind? What adjustments or pivots are needed to finish the year strong?
Leaders align on key actions based on market conditions and key business metrics. Excellence in execution is often determined by how a leader articulates a course correction to the field with enough urgency to matter and enough context to be trusted.
The team understand and aligns to a deliberate adjustment from a business that is paying attention when handled well. The same content lands as upheaval when handled poorly, and the field spends the fourth quarter recalibrating its trust instead of its plans. When we support leaders through this moment, the same three questions surface in nearly every engagement. They deserve direct answers.
How do I communicate a change in priorities to a pharma field team in the fourth quarter?
Start by being clear with yourself about which kind of correction you are making. One is a change of pace, doing more of what is already working, with more urgency. The other is a change of direction, redirecting focus to different accounts, different stakeholders, different activity. Most organizations default to the first because it requires no decision.
Once that is settled, the structure that works is simple and disciplined. Three questions, answered in order for every audience from the leadership team to the newest rep:
- What stays the same, and why. Continuity comes first. Most of the strategy usually survives intact, and saying so explicitly prevents the field from assuming everything is in play.
- What changes, and what prompted it. Connect each adjustment to something the team can verify: a marketplace shift, an account change, an insight gleaned from the first-half. Changes with visible cause read as responsiveness. Changes without them are perceived as churn.
- What each person does differently starting Monday. Priorities that never reach the level of individual behavior are sentiments, not decisions. The conversation is not finished until every team member can name what changes in their own week.
Sequence matters as much as content. Leaders who open with the changes trigger the field’s threat response before the context arrives. Leaders who open with continuity earn the attention the changes require.
How do biopharma leaders refocus a team in September without hurting morale?
Morale rarely suffers because things change. It suffers when people conclude the change is a verdict on their effort so far, on their standing, or on leadership’s confidence in the plan they executed.
Three leadership behaviors which set the right tone:
- Acknowledge the work already done before redirecting it. Adjustment built on acknowledged effort feels like progress. Adjustment that skips the acknowledgment feels like criticism.
- Let the team put its fingerprints on the “how.” The priorities may not be negotiable. How each team translates them usually is, and involvement is critical to commitment.
- Treat this as a rhythm, not an event. Teams that only hear about adjustments twice a year experience each one as an isolated event. Teams whose leaders normalize continuous learning and refinement experience it as the way the business runs.
The leaders who do this well are not softer communicators. They are more deliberate ones, and their teams close the year stronger because the Fall was spent executing rather than wondering.
How often should biopharma commercial teams revisit priorities during the year?
The formal moments, mid-year and year-end, are the natural points for a structured reset, and this month sits between them for a reason. If accounts are always changing, and they are, then priority review cannot live only at the checkpoints. The healthiest operating rhythm looks like this:
- Continuously: teams surface what has shifted, through the ordinary flow of business reviews and coaching conversations.
- Quarterly: leaders ask whether any adjustments warrant a change in priorities, and whether there are identified changes or not, the decisions are worth saying aloud.
- At the formal moments: the fuller conversation this article describes, where continuity, change, and individual translation all get explicit attention.
Striking a balance is important: push refinement constantly and the team never gets traction; reserve it for twice a year and the plan drifts between conversations. Leaders who can articulate between ongoing refinement versus more intention shifts in priorities and actions get the benefit of both.
September is a key inflection point in the business cycle. Key learnings and insights are shared: an account that changed hands, access that has narrowed, a stakeholder whose influence has grown, are the same insights required to shape next year’s plan. The conversation that refocuses the team for the fourth quarter is also the one that informs or refines the 2027 plan. All of which lead to the question leaders ask when they decide they want help.
Who helps pharma commercial leaders run team alignment and priority-reset sessions?
The providers differ more than their websites suggest. The differences show up in three places:
- Grounding in organizational science. Alignment sessions fail when they are facilitation theater: energetic, pleasant, and easily forgotten. Look for an approach built on how teams actually adopt priorities and change behavior.
- Preparation of the leader, not just the attendees in the room. The session matters less than how the leader carries the message afterward.
- Design for your business rhythm. A Fall reset in biopharma lands amid 2027 brand planning, budget season, and POA preparation. A partner who can seamlessly work within that calendar helps drive more valuable outcomes.
This is the thinking behind WLH’s Team Jump Start. If your team’s fourth quarter would benefit from a structured reset, we would welcome a conversation.
